Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity
Alimta Reduces Risk Of Progression In Patients Aged 70 Years or Older
Family History of BRCA Mutation Does Not Equal Increased Risk
Daily Vitamin E Supplements Can Lead to Increased PCa Risk
Digital Immunoassay PSA Test May Predict Cancer Recurrence
Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV
Researchers Discover Bacteria Common in Colon Cancer Tissue
Colon Cancer Survival Rates Differ Across Racial Lines
NCI Predicts 42 Percent Increase In Number of Senior Survivors
IMRT Less Toxic Than 3D-CRT In Localized Prostate Cancer
NCI CTEP: Approved Trials For The Month of October
FDA Grants Accelerated Approval To Ferriprox for Iron Overload
Trending Stories
- Trump 2016: A look back at the 45th president’s impact on oncology
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
